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S U M M A R Y
Background: Bone and joint tuberculosis (BJTB) constitutes about 10–20% of the extrapulmonary
tuberculosis (EPTB) cases in China. The GenoType MTBDRplus assay (MTBDR) has been endorsed by the
World Health Organization (WHO) for the diagnosis of pulmonary TB (PTB), while the Xpert MTB/RIF
assay (Xpert) has also been endorsed by the WHO for the diagnosis of both PTB and EPTB. The diagnostic
utility of these two techniques for BJTB was investigated prospectively.
Methods: Sixty pus specimens were obtained from orthopedic patients. Smear, culture, Xpert, and
MTBDR assays were performed for each specimen, and MGIT 960-based drug susceptibility testing (DST)
was conducted for all of the isolates recovered. The diagnostic efﬁciency of Xpert and MTBDR was
evaluated on the basis of bacteriological examination and the composite reference standard (CRS).
Results: Fifty of the 60 patients were considered to have BJTB according to the CRS. The sensitivities of
smear, culture, Xpert, and MTBDR were 26% (13/50), 48% (24/50), 82% (41/50), and 72% (36/50)
respectively, while the speciﬁcities of all of the tests were 100% (10/10). Xpert was 100% concordant with
MGIT 960-based DST for the detection of rifampicin resistance. MTBDR had a sensitivity of 83.3% and a
speciﬁcity of 100% for the detection of rifampicin resistance and a sensitivity of 85.7% and speciﬁcity of
100% for the detection of isoniazid resistance.
Conclusion: With their high sensitivities, short turnaround times, and ability to diagnose TB and detect
drug resistance simultaneously, both Xpert and MTBDR are feasible as diagnostic tools for BJTB in clinical
practice.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) remains one of the predominant infectious
diseases affecting adults in developing countries.1 China ranks
second among the 22 high-burden countries that together account
for 80% of TB cases and 22% of multidrug-resistant TB (MDR-TB)
cases worldwide.2 Extrapulmonary TB (EPTB) accounts for about
10–20% of all cases of active TB in China,3 and among cases of EPTB,
38.6% is lymph node TB, 19.9% is bone and joint TB (BJTB), 16.7% is
urinary and genital TB, 9.1% is intestinal and peritoneal TB, and* Corresponding author. Tel.: +86-10-89509159.
E-mail addresses: qinsb@sina.com (S. Qin), huanghairong@tb123.org
(H. Huang).
1 Yunting Gu and Guirong Wang contributed equally to this study.
http://dx.doi.org/10.1016/j.ijid.2015.05.014
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).6.4% is cerebral and nervous system TB.4 Therefore, rapid BJTB case
detection and the early identiﬁcation of patients with MDR-TB
have become extremely important in high-burden countries such
as China.
The diagnosis of BJTB is challenging due to limitations in
sampling from the affected sites and the paucibacillary nature of
the specimens. Limitations in sensitivity, the amount of time
required for assays, and the requirement for invasive procedures
and expertise render the conventional diagnostics of BJTB less
efﬁcient. In the last decade, molecular tests have been developed to
detect the presence of Mycobacterium tuberculosis bacilli and to
identify mutations conferring resistance to the most important
ﬁrst-line TB antibiotics, isoniazid (INH) and/or rifampicin (RIF).5,6
In 2008 the GenoType MTBDRplus assay (MTBDR), which detects
resistance to both INH and RIF within 48 h, was endorsed by theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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TB (PTB).7 In 2010, another assay was endorsed by the WHO for the
diagnosis of PTB, known as the Xpert MTB/RIF assay (Xpert).8 As a
fully automated real-time PCR technique,9 Xpert can provide RIF
susceptibility results within 2 h.10,11 Since Xpert also has
comparable performance to the composite reference standard
(CRS) for detecting EPTB,12 the WHO recommended Xpert for the
diagnosis of EPTB in 2013.13
A series of meta-analyses have shown that nucleic acid
ampliﬁcation tests (NAATs) have high speciﬁcity, high positive
predictive value, and highly variable sensitivity for the diagnosis of
EPTB.14–16 However, both MTBDR and Xpert are yet to be
rigorously evaluated for specimens collected from BJTB. Previous
studies have involved the comparison of molecular tests with the
outcomes of culture, which is known to be a very suboptimal
reference standard for EPTB. Therefore in this study, the CRS17 was
used in addition to culture in order to evaluate the realistic
diagnostic efﬁciency of Xpert and MTBDR for BJTB.
2. Materials and methods
2.1. Ethics statement
Ethical approval for this study was obtained from the Beijing
Chest Hospital Ethics Committee. Written informed consent was
acquired from each participant.
2.2. Patient categories
Sixty patients with suspected BJTB were recruited between
March and June 2014 from the Beijing Chest Hospital. These
patients who were diagnosed with suspected BJTB had pus
specimens collected during operations, and before operations,
and all had been administered anti-TB treatment for at least
2 weeks. Pus specimens of at least 5 ml were collected under sterile
conditions from each of the 60 orthopedic patients during surgical
debridement.
Based on the CRS, patients were categorized into four groups:
(1) conﬁrmed BJTB cases (culture-positive), (2) probable BJTB
cases (culture-negative but biopsy or surgical specimens showed
caseating granuloma and the patient responded well to anti-TB
therapy), (3) possible BJTB cases (responded to anti-TB therapy
and had radiographic ﬁndings consistent with osteoarticular TB,
but lacked bacteriological and histopathological corroborating
evidence), and (4) non-TB (culture and all other tests for TB were
negative and the patient improved without receiving TB
treatment).17
2.3. Smear microscopy
Direct smears were prepared from the specimen and stained
using the auramine staining technique. The specimens were then
examined by light-emitting diode (LED) microscopy. The smears
were read and interpreted in accordance with the WHO guide-
lines.18
2.4. Mycobacterial culture and susceptibility testing by MGIT 960
Two milliliters of pus specimen were decontaminated with N-
acetyl-L-cysteine sodium hydroxide (BBL MycoPrep; Becton
Dickinson, Sparks, MD, USA) for 20 min, neutralized with sterile
phosphate-buffered saline (PBS, pH 6.8), added to a ﬁnal volume of
45 ml, and centrifuged at 3000 g for 15 min at 4 8C. The
supernatant was discarded, and the remaining pellet was
resuspended in 1.5 ml of PBS. Each MGIT 960 tube was inoculated
with 0.5 ml of the resulting specimen, incubated at 37 8C in anautomated MGIT 960 apparatus (Becton Dickinson) for a maxi-
mum of 42 days, and monitored continuously. The MGIT 960 out-
comes were recorded as per the manufacturer’s instructions.
Standard drug susceptibility testing (DST) with INH and RIF was
carried out for the positive cultures using the MGIT 960 IR kit
(Becton Dickinson) following the manufacturer’s instructions.
2.5. GenoType MTBDRplus assay
The DNA template for PCR was extracted from 1 ml of pus
specimen using a GenoLyse kit (Hain Lifescience GmbH, Nehren,
Germany). PCR ampliﬁcation, hybridization, and the interpretation
of outcomes were performed in accordance with the manufac-
turer’s instructions (Hain Lifescience).19
2.6. Xpert MTB/RIF assay
The assay was performed as per the manufacturer’s instructions
(Cepheid, Sunnyvale, CA, USA). Brieﬂy, 1 ml of pus specimen was
mixed with 2 ml Xpert sample reagent, vortexed for at least 10 s,
and incubated at room temperature for 10 min. The mixture was
again vortexed for another 10 s and incubated at room temperature
for 5 min. A total of 2 ml of the mixture was transferred into the
Xpert cartridge and loaded into the GeneXpert instrument. The
automatic detection procedure was then run.
3. Results
3.1. Patients categorized by CRS
According to the CRS, 50 patients were considered to have BJTB
and 10 patients to have no evidence of TB. Of these 50 BJTB
patients, 24 (40%) were culture-positive ‘conﬁrmed BJTB’ cases, 22
(36.67%) were ‘probable BJTB’ cases, four (6.67%) were ‘possible
BJTB’ cases, and 10 (16.67%) patients had no evidence of TB. Table 1
shows the demographic characteristics of patients in the different
categories. According to the CRS, conﬁrmed BJTB patients had a
longer duration of illness (18  20 months) than those in the other
three categories of patient (8  8 months, 8  8 months, and
7  10 months, respectively). Among the 24 conﬁrmed BJTB patients,
six (25%) were determined to have MDR-TB upon phenotypic DST.
3.2. Sensitivity and speciﬁcity of Xpert and MTBDR tests
According to the CRS, the sensitivities of smears, culture, Xpert,
and MTBDR tests were 26% (13/50), 48% (24/50), 82% (41/50), and
72% (36/50) respectively, while their speciﬁcities were 100% (10/
10). The sensitivities of Xpert and MTBDR were 100% (24/24) and
87.5% (21/24) for conﬁrmed BJTB, 72.73% (16/22) and 63.64% (14/
22) for probable BJTB, and both were 25% (1/4) for possible BJTB.
Both the Xpert and MTBDR test detected all smear-positive
specimens, whereas Xpert detected all of the smear-negative/
culture-positive specimens but the MTBDR test detected only 75%
(9/12) of these. It is worth mentioning that the Xpert and MTBDR
tests produced positive outcomes for 64% (16/25) and 56% (14/25),
respectively, of smear-negative/culture-negative/CRS-supposed
BJTB patients.
3.3. Detection of drug resistance
Standard MGIT 960 DST was performed for the 24 M.
tuberculosis isolates recovered from pus samples. Six RIF-resistant
isolates and seven INH-resistant isolates were identiﬁed by MGIT
DST (six MDR strains and one INH mono-resistant strain) (Table 2).
Xpert was 100% concordant with MGIT DST with regard to the
detection of RIF resistance. Compared to phenotypic DST, MTBDR
Table 1
Demographic characteristics of patients in the different categoriesa
Characteristics Conﬁrmed BJTB
(n = 24)
Probable BJTB
(n = 22)
Possible BJTB
(n = 4)
Non-TB
(n = 10)
Age, years 42 (18–82) 33 (21–77) 19 (16–28) 57 (21–70)
Male 11 (45.83%) 8 (36.36%) 2 (50%) 7 (70%)
Spine lesion 18 (75%) 16 (72.73%) 3 (75%) 5 (50%)
Joint lesion 6 (25%) 6 (27.27%) 1 (25%) 5 (50%)
Duration of illness, months 18  20 (2–96) 8  8 (1–24) 8  8 (1–18) 7  10 (1–36)
Responded well to anti-TB treatment 23 (95.83%) 22 (100%) 4 (100%) 0
Period of anti-TB treatment before sample collection,
months
1.45  2.80 (0.5–12) 1.80  1.66 (0.5–16) 12.33  15.31 (3–30) 1.25  1.03 (0.5–3)
Bone destruction
1 vertebral body 1 (4.17%) 2 (9.09%) 1 (25%) 0
2 vertebral bodies 13 (54.17%) 13 (59.09%) 1 (25%) 3 (30%)
3 vertebral bodies 0 1 (4.55%) 0 2 (20%)
4 vertebral bodies 3 (12.5%) 0 0 0
BJTB, bone and joint tuberculosis; TB, tuberculosis.
a Data are presented as the median (range), number (percentage), or mean  standard deviation (range).
Table 2
Sensitivities and speciﬁcities of the Xpert MTB/RIF and GenoType MTBDRplus tests for the detection of rifampicin and/or isoniazid resistance in comparison with drug
susceptibility testing
Method Sensitivity for RIF Resistance (%) Speciﬁcity for RIF Resistance (%) Sensitivity for INH Resistance (%) Speciﬁcity for INH Resistance (%)
Xpert 6/6 (100) 18/18 (100) - -
MTBDR 5/6 (83.33) 18/18 (100) 6/7 (85.71) 17/17 (100)
RIF, rifampicin, INH, isoniazid.
Y. Gu et al. / International Journal of Infectious Diseases 36 (2015) 27–30 29missed one case of RIF resistance and one case of INH resistance,
resulting in a sensitivity of 83.33% and 85.71%, respectively. The
MTBDR test had 100% speciﬁcity for the detection of resistance to
both drugs.
4. Discussion
A few studies have shown the effectiveness of Xpert in the
diagnosis of EPTB,20,21 in which the reported sensitivity ranged
from 87.3% to 95% and the speciﬁcity in contrast to CRS was
consistently over 97%. In the present study, the performance of the
Xpert and MTBDR assays in the diagnosis of BJTB using pus
specimens was investigated. Among the sample recruited, the
sensitivities of the Xpert and MTBDR tests were 82% (41/50) and
72% (36/50), respectively, while their speciﬁcities were 100%
according to the CRS, a value similar to those reported from
previous studies mainly focusing on other forms of EPTB.
In the present study, according to the CRS, Xpert and MTBDR
identiﬁed 75.68% (28/37) and 62.16% (23/37) of smear-negative
specimens, as well as 65.38% (17/26) and 57.69% (15/26) of
culture-negative specimens, respectively. The low sensitivity of
culture (48%) in comparison with that of the molecular tests (72–
82%) against the CRS can be explained as follows:21 (1) all of the
BJTB patients in this assay had undergone anti-TB treatment for
various periods of time before sample collection, which is believed
to affect the recovery rate of culture more than the outcome of
molecular tests; (2) the paucibacillary nature of pus specimens
with a tendency of M. tuberculosis to form clumps led to an uneven
distribution of the bacilli; and (3) there was a loss of viable bacilli
during decontamination.
Due to the small number of patients in the possible BJTB and
non-TB categories, further demographic characteristics could not
be analyzed. However, the conﬁrmed BJTB category of patients
seemed to have a notably longer duration of illness than the other
three categories of patients (Table 1). This phenomenon is
consistent with the general observation that the longer the
duration of illness, the more severe the disease is, and the more
chance of obtaining bacteriological evidence to conﬁrm the
diagnosis of TB.A clear advantage of molecular tests is their rapid turnaround
time. For patients with a positive molecular test result, the time
needed to obtain bacterial evidence of TB is reduced dramatically
from a few weeks to a few days. BJTB cases used to be treated
empirically on clinical and radiological grounds, and a full course of
anti-TB chemotherapy was also required.22 Early determination of
the identity and sensitivity of the mycobacteria is very important
not just from a public health and epidemiological perspective, but
also for treatment and management.23 The presence of MDR-TB
has resulted in a less efﬁcient and more prolonged and complicated
course of treatment. Obtaining conventional DST results takes at
least 2 months from sample collection to the outcome, while
molecular tests make it possible for the appropriate management
of MDR-TB to be started without delay.24
In this study, the sensitivity of Xpert for detecting RIF resistance
was shown to be 100%, and the sensitivities of MTBDR in the
detection of RIF and INH resistance were 83.3% and 85.7%,
respectively. Xpert demonstrated a higher sensitivity characteris-
tic than the MTBDR in this assay, and this merit may be the result of
the sample processing method, inoculum size, and the full
automation steps.24 MTBDR requires several manual steps to
prepare the DNA template, which might cause the loss of DNA
during processing; the manual hybridization step could also
decrease the sensitivity of the assay. However, the Xpert assay only
detects RIF resistance, which might lead to an over-estimation of
MDR-TB in regions where RIF mono-resistance is frequently seen.
Although in this scenario, MTBDR has an advantage over Xpert, the
drawbacks such as redundancy of operation and subjective
interpretation of the outcome, decrease the feasibility of this
assay.25
In conclusion, both Xpert and MTBDR are feasible diagnostic
tools for BJTB, with high sensitivity, a short turnaround time, and
the ability to diagnose TB and detect drug resistance simulta-
neously.
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